Background {#Sec1}
==========

Glycogen storage diseases (GSDs) are disorders of the metabolism of glycogen which result from mutations in the genes involved in either the synthesis and degradation of glycogen or the regulation of glycogen metabolism. They have been categorized by number according to the recognition of the responsible enzyme defect \[[@CR1]\]. The age at onset of disease varies from in utero to adulthood. Patients may have various clinical presentations, including exercise intolerance, myalgias, myoglobinuria, severe hypoglycemia, hepatomegaly, and cardiomyopathy. When subjected to anesthesia, these patients are at risk for the development of hypoglycemia, rhabdomyolysis, myoglobinuria, and acute renal failure \[[@CR2]--[@CR7]\]. The aim of this study was to characterize the perioperative course of patients with GSDs who underwent anesthetic management at a single tertiary medical center.

Methods {#Sec2}
=======

This study was approved by the Mayo Clinic Institutional Review Board study, (Study ID 15--004738, approval date July 6, 2015, by Ellen Olson). Consistent with Minnesota Statute 144.335, we included only patients who had provided authorization for research use of their medical records.

We searched our institutional patient database to identify the records of patients with GSDs who underwent surgeries or procedures with anesthetic management at Mayo Clinic, Rochester, Minnesota, between January 1, 1990, and June 31, 2015. The diagnosis of GSD was made through clinical signs and symptoms and was confirmed by muscle biopsy, liver biopsy, or genetic testing. For all patients identified, the records were reviewed for demographics, preexisting comorbid conditions, surgical/procedural records, anesthetic type and course, and type of fluids used intraoperatively. We also reviewed preoperative, intraoperative, and postoperative laboratory values, with particular attention to arterial pH and serum glucose, and lactate levels as potential markers of metabolic decompensation. Hypoglycemia was defined as blood glucose concentrations of 70 mg/dL or lower \[[@CR8]\]; and metabolic acidosis was defined as pH imbalance due to a reduction in bicarbonate (HCO3−) of 22 mmol/L or lower, which was not a result from secondary causes, e.g., chronic respiratory alkalosis. In addition, we reviewed postoperative course and patient disposition (eg, admission to general medical unit or intensive care unit, or outpatient procedure) and any complications within 30 postoperative days. Demographics and perioperative characteristics were summarized using descriptive statistics.

Results {#Sec3}
=======

Our search of the database identified 30 patients with GSD who underwent 41 procedures under anesthesia management.

Preoperative clinical characteristics {#Sec4}
-------------------------------------

Table [1](#Tab1){ref-type="table"} shows the clinical characteristics of patients with GSD, which varied depending on the specific disorder. Patients with type I disorder (von Gierke disease) primarily had metabolic disorders consisting of hypoglycemia. Patients with type II (Pompe disease) and type V (McArdle disease) often had myopathy and muscle weakness. Patients with type II disorder often had respiratory failure related to myopathy or muscle weakness and heart failure from hypertrophic cardiomyopathy. Two of these patients (\#13 and \#15) underwent preoperative Holter monitoring: sinus tachycardia (fastest heart rate, 137 beats/min) was detected in patient \#13, and ventricular tachycardia (fastest heart rate, 163 beats/min) was detected in patient \#15. Cardiac manifestations were also present in the patient with type 0 disorder. Patients with other types of GSD typically had muscle weakness, myopathy, or hepatosplenomegaly, or a combination of these.Table 1Clinical characteristics of study patients with glycogen storage diseaseClinical presentationPtNeurologic/MuscularOtherGSD type 0 1Muscle weaknessOSA; hypertrophic cardiomyopathy; hypertensionGSD type I (von Gierke) 2Muscle weakness; gait abnormalitiesLactic acidosis; hypoglycemia; hepatic adenoma 3None reportedHypoglycemia 4None reportedHypertension; hypoglycemia; lactic acidosis 5SeizuresHyperuricemia; lactic acidosis; hypoglycemia 6Developmental delay; velopharyngeal insufficiencyHypoglycemia 7Fatigue, muscle weaknessHypoglycemiaGSD type II (Pompe) 8Severe scoliosis; muscle weakness; wheelchair-boundRespiratory failure (BiPAP); restricted lung disease 9Muscle weakness; hypotoniaNone reported 10Muscle weaknessRespiratory failure (BiPAP); pulmonary hypertension; CHF; dilated cardiomyopathy; atrial fibrillation 11Muscle weaknessNone reported 12Muscle weaknessCHF; dilated cardiomyopathy 13Muscle weaknessRespiratory failure (BiPAP) 14Muscle weaknessDyspnea; hypertension 15None reportedHypertrophic cardiomyopathy; ventricular tachycardiaGSD type IV (Andersen) 16Developmental delayHepatosplenomegalyGSD type V (McArdle) 17Muscle weakness; cervical radiculopathyNone reported 18Muscle stiffness; increased serum creatine kinaseNone reported 19Muscle weaknessNone reported 20Muscle weaknessNone reported 21Muscle cramps; exercise intoleranceNone reported 22Exercise intoleranceNone reported 23Muscle weaknessNone reported 24Muscle weakness and stiffnessNone reported 25Muscle weaknessNone reported 26Episodes of rhabdomyolysis; exercise intoleranceNone reported 27Muscle weaknessHypertensionGSD type VI (Hers) 28None reportedLactic acidosisGSD type VII (Tarui) 29Muscle weaknessNone reportedUnidentified, likely glycolytic defect 30Proximal muscle myopathyHypoglycemia*Abbreviations*: *BiPAP* bilevel positive airway pressure, *CHF* congestive heart failure, *GI* gastrointestinal, *MH* malignant hyperthermia, *OSA* obstructive sleep apnea, *Pt* patient

Anesthesia course and Intraoperative fluid administration {#Sec5}
---------------------------------------------------------

Case mix and anesthetic management is summarized in Table [2](#Tab2){ref-type="table"}. Twenty-two procedures were outpatient based. Twenty-eight procedures were performed under general anesthesia, of which 23 were performed with endotracheal intubation and 5 with a laryngeal mask airway. The other 13 procedures were performed under monitored anesthesia care. Most patients underwent either diagnostic biopsies (*n* = 20) or minor procedures (*n* = 13) (e.g., dilation and curettage, reduction mammoplasty, gastric tube placement). The other patients (*n* = 8) underwent extensive operations: liver transplant (*n* = 3), myectomy (n = 1), Whipple procedure (n = 1), and spinal fusion (n = 3).Table 2Case mix, surgical and anesthetic characteristics in patients with glycogen storage diseasePtAge^a^ at Surgery, ySurgery/Anesthesia duration, min/Airway/Anesthetic AgentsFluid usedDispositionGSD type 0151--60Muscle biopsy/120,PLROutpatientGSD type I (Von Gierke)219--30Liver transplant/360/P, C, S, IsoNS; D5W; PRBC; Cryo; AlbuminICU311--18Liver transplant/300/P, C, IsoNS; D5W; AlbuminICU46--10Liver transplant/330/P, V, IsoNS; D5NS; PRBC; AlbuminICU51--2Muscle biopsy/120/Sev, N~2~OD5NSOutpatient1--2Gastric tube placement/60/P, At, IsoD10NSWard6\<1Gastric tube placement/100/P, At, SevLR; D10NSWard3--5Tonsillectomy/110/P, VLR; D10NSWard3--5Myringotomy/ 100/PLR; D10NSWard711--18Rectal abscess I&D/70/At, STP, N~2~OD10WOutpatient11--18Abscess I&D/120/P, At, N~2~OLR; D10WOutpatientGSD type II (Pompe)811--18Anterior spinal fusion/300/STP, Iso, Sev, PLR; PRBC; FFP; Platelets; Hetastarch; AlbuminICU11--18Posterior spinal fusion/730/P, Sev, N~2~OLRICU9\<1Muscle biopsy/75/P, N~2~OLROutpatient1041--50Muscle biopsy/MAC/60, PLR; NSWard41--50Tracheostomy/80/E, S, SevLRICU1151--60Muscle biopsy/MAC/90 mask, PNSOutpatient 1231--40Myocardial biopsy/MAC/90, Mz, ALLROutpatient31--40Parathyroidectomy/120/E, V, IsoLRWard1341--50Muscle biopsy/MAC/60,PLRICU1441--50Muscle biopsy/MAC/120/ Mask, PNS; LR; AlbuminOutpatient153--5Myectomy (ICD)/ CPB/280,Sev, V, IsoLRICU3--5Sternal wire removal/180/E, RO, SevWardGlycogen storage disease type IV (Andersen)161--2Liver biopsy/MAC/60/ Mask, SevLROutpatient1--2Myringotomy/GA/60/Sev, N~2~ONoneOutpatient1761--70Cervical discectomy/200, P, ROWardGlycogen storage disease type V (McArdle)1811--18Muscle biopsy/60)/ LMA/Sev, N~2~OLROutpatient196--10Muscle biopsy/60/P, Sev, N~2~OLROutpatient2041--50Whipple /GA /360/P, S, V, IsoLRWard2141--50Muscle biopsy/MAC/60/ Mask/PLROutpatient2211--18Muscle biopsy/MAC/90/ Mask/P, SevLROutpatient2319--30Muscle biopsy/ MAC/105/ Mask, PLROutpatient2419--30Muscle biopsy/ MAC/60/ Mask, PLROutpatient256--10Muscle biopsy/70/ LMA, PLROutpatient2619--30Muscle biopsy/ MAC/120/ Mask, PLROutpatient27\>70Muscle biopsy/MAC/60/ Mask, PLROutpatientGSD type VI (Hers)281--2Liver biopsy/105/Sev, ROD5NSOutpatientGSD type VII (Tarui)2961--70Muscle biopsy/MAC/210/Mask, PLROutpatientUnidentified, likely glycolytic defect3031--40Dilation & curettage/60/LMA/P, N~2~OLROutpatient31--40Mammoplasty/240/P, V, N~2~OLRWard31--40Breast hematoma evacuation/90/LMA/P, N~2~OLRWard*Abbreviations*: *At* atracurium, *BiPAP* bilevel positive airway pressure, *C* cisatracurium, *CPB* cardiopulmonary bypass, *D10NS* 10% dextrose with 0.9% normal saline, *D10W* 10% dextrose with water, *D5NS* 5% dextrose with 0.9% normal saline, *D5W* 5% dextrose with water, *E* etomidate, *F* female, *GA* general anesthesia, *ICD* implantable cardioverter-defibrillator; *ICU* intensive care unit, *I&D* incision and drainage, *Iso* isoflurane, *LMA* laryngeal mask airway, *M* male, *Mz* midazolam, *MAC* monitored anesthesia care, *N* ~*2*~ *O* nitrous oxide, *NA* not available, *NS* 0.9% normal saline, *P* propofol, *PRBC* packed red blood cells transfusion, *Pt* patient, *RO* rocuronium, *S* succinylcholine, *Sev* sevoflurane, *STP* sodium thiopental, *V* vecuronium^a^Age is reported as a range (in year): \<1 year; 1--2; 3--5; 6--10; 11--18; 19--30; 31--40; 41--50; 51--60; 61--70; \>70

Nondepolarizing neuromuscular blocking drugs were administered in 16 patients, and succinylcholine was used in 3, without adverse effects, including patients with Pompe disease and preexisting muscle weakness. Propofol infusions were used in 14 cases. Lactated Ringer's solution was used in 33 procedures (80%), but patients with a history of hypoglycemia were intraoperatively administered dextrose-containing solutions, including all patients with type I. Among patients with type I, 2 of them (\#2 and \#5) had hypoglycemia preoperatively and 3 (\#3, \#4, and \#15) had borderline low glucose levels (71--75 mg/dL). Patients \#2 and \#3 developed hypoglycemia during orthotopic liver transplant surgery (59 and 34 mg/dL, respectively). Perioperative mild metabolic acidosis developed in 4 patients undergoing orthotopic liver transplant and myectomy, which resolved within 24 postoperative hours.

Postoperative course {#Sec6}
--------------------

No clinically significant postoperative complications occurred among the group (Table [2](#Tab2){ref-type="table"}). There were no unexpected intensive care unit admissions, and all patients admitted to the intensive care unit were discharged to a regular postoperative ward within 24 h.

Discussion {#Sec7}
==========

The most important observation of this study was that patients with GSDs, despite having substantial comorbid conditions, tolerated surgery and anesthesia without major complications. Self-limited, transient, metabolic acidosis developed in several patients undergoing major surgical procedures, during which it may be expected however, it remains unclear whether underlying metabolic disorder was a contributing factor. Another important observation was that hypoglycemia was present in some patients with GSD type I. In this subset of patients, it is prudent to use glucose-containing fluids and closely monitor glucose levels.

GSD type I (von Gierke disease) {#Sec8}
-------------------------------

Patients with type I are at increased risk for perioperative metabolic and homeostatic derangements, particularly hypoglycemia. These abnormalities are mainly related to a defect of either glucose-6-phosphatase or glucose-6-phosphatase transporter, which impairs the production of glucose via either gluconeogenesis or glycogenosis. Accordingly, frequent monitoring of blood glucose is recommended during the perioperative period \[[@CR1], [@CR9]--[@CR11]\] especially during major procedures. In our series, patients with hypoglycemia were administered dextrose-containing solutions during their procedures. Patient \#4 had intraoperative hypoglycemia (34 mg/dL), he received a dextrose solution infusion, and all subsequent glucose checks were above 100 mg/dL. This patient underwent liver transplant, which in itself can contribute the glucose metabolism impairment and can potentially cause hypoglycemia. Patients with type I disease are also prone to the development of organic acidemias; in this series, the 3 patients who underwent liver transplant were known to have lactic acidosis (patients \#2, \#3, and \#4). Lactate ringer solution (LR) was used for 7 minor procedures without incident, albeit in patients without known organic acidemias, and in conjunction with dextrose-containing solutions.

Patients with type I are also at risk for the development of pancreatitis secondary to hypertriglyceridemia \[[@CR1], [@CR12]\]. Bustamante and Appachi \[[@CR11]\] reported a case of pancreatitis in a 4-year-old girl with type I undergoing general anesthesia for tonsillectomy with propofol infusion. In our series, the 3 patients undergoing liver transplant received propofol infusion as a part of their anesthetic, with an average of 12 h' duration, withoutadverse effects. Patient with GDS type I may also have coagulation abnormalities arising from acquired von Willebrand factor abnormalities, and the perioperative use of desmopressin advocated to facilitate hemostasis \[[@CR13], [@CR14]\]. However, in our cohort the perioperative records did not indicate coagulopathy.

GSD type II (Pompe disease) {#Sec9}
---------------------------

Patients with type II may have marked hypertrophic cardiomyopathy and an increased risk of dysrhythmia \[[@CR15], [@CR16]\]. Cases of intraoperative cardiac arrest have been described \[[@CR17], [@CR18]\]. Therefore, preoperative electrocardiography and echocardiography should be considered to assess both cardiac rhythm and function. Wang \[[@CR15]\] described ventricular and supraventricular dysrhythmias in 9 infants with type II disease soon after the induction of general anesthesia with propofol and/or sevoflurane. Two of these patients died intraoperatively as a result of dysrhythmias. In our series, preoperative electrocardiography was performed in most patients with Pompe disease, and 2 of our patients (\#13 and \#15) undergoing muscle biopsy and septal myectomy had preoperative echocardiography and Holter monitoring. No perioperative dysrhythmias were noted in this subset of patients.

Type II disease is also known for skeletal muscle myopathies. These may lead to weakness of the respiratory muscles, which further leads to chronic respiratory failure \[[@CR19]\] and increased risk of postoperative respiratory complications \[[@CR20]\]. Indeed, 4 of our patients (\#8, \#10, \#13, and \#14) had known respiratory symptoms preoperatively. One patient (\#10) underwent elective tracheostomy for management of chronic hypercarbic respiratory failure. Fortunately, none of our patients had acute worsening of respiratory symptoms postoperatively. Muscle relaxation with nondepolarizing agents should be used cautiously because residual weakness could be poorly tolerated. However, these drugs were used in 3 cases (\#10, \#12, and \#15) without incident.

GSD type V (McArdle disease) {#Sec10}
----------------------------

Patients with type V disease may have rhabdomyolysis, myoglobinuria, and acute renal failure \[[@CR2]\]. Cases of acute renal failure have been reported after strenuous or vigorous exercise \[[@CR3], [@CR4]\] and after an asthmatic attack \[[@CR5]\]. Cases of massive rhabdomyolysis and myoglobinuria also have been observed after a diagnostic forearm ischemic work test using a tourniquet \[[@CR2], [@CR21]\]. Indeed, particular attention should be paid to intraoperative positioning because improper positioning can increase the risk of rhabdomyolysis. In our series, most patients with type V had a chronically high creatine kinase level, but patients had no abnormal temperature fluctuations, signs of hypermetabolism, or signs of rhabdomyolysis in the perioperative period. In this study, potential malignant hyperthermia triggers---volatile anesthetics and succinylcholine---were used in 4 cases (\#18, \#19, \#20, and \#22) with no clinical complications observed. Despite reported suspected cases of malignant hyperthermia in the type V disease \[[@CR2], [@CR22], [@CR23]\], the U.S. Malignant Hyperthermia Association has stated that there is no association between any type of GSD and malignant hyperthermia \[[@CR24]\].

GSD type 0, IV, VI, and VII {#Sec11}
---------------------------

To our knowledge, there are no reported cases of patients with type 0, IV, VI, or VII undergoing anesthesia who had perioperative complications related to their disease. It is known that types 0, IV, and VI affect the liver and that patients might experience mild hypoglycemia, whereas type VII primarily affects the muscle, which results in muscle weakness and myalgia. Any potential challenges related to anesthesia care in these patients are still uncertain. In our case series, the 4 patients with type IV, VI, VII, and 0 (\#16, \#28, \#29 and \#30, respectively), who underwent liver biopsy in the first 2 cases and muscle biopsy in the other 2, tolerated anesthesia well with no major perioperative complications. They were discharged the day of surgery. Because of the lack of previous reports and the limitations of our case series, no definitive recommendations can be made regarding anesthesia with these 4 GSD types. Further larger studies are warranted.

Limitations {#Sec12}
-----------

This study has all the inherent limitations of a retrospective study design. Moreover in our cohort none of the patients included in the study underwent regional anesthesia, thus our experience with anesthetic technique is limited.

Conclusions {#Sec13}
===========

In our study, patients with various types of GSD undergoing anesthesia did not experience complications that could be attributed to anesthesia, per se. Hypoglycemia must be prevented in patients with type I (von Gierke disease), and thorough assessment of cardiac and pulmonary function is needed in type II (Pompe disease). Patients with type I (von Gierke disease) are also prone to the development of organic acidemias, but we did not encounter severe acid-base disturbances despite intraoperative administration of LR in some patients.
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